Recently, a CRISPR interference system has been utilised to selectively deacetylate histones in the TGFβ2 gene promoter, reducing TGFβ2 expression in human TM cells and ameliorating ocular hypertension in a TGFβ2-overexpressing mouse model [107]. The gene discussed is TGFB2; the disease is ocular hypertension.